Use of EMPAgliflozin in the prevention of CARDiotoxicity: the EMPACARD – PILOT trial
Crossref DOI link: https://doi.org/10.1186/s40959-024-00260-y
Published Online: 2024-09-05
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Daniele, Andrés J.
Gregorietti, Vanesa
Costa, Diego
López – Fernández, Teresa
Text and Data Mining valid from 2024-09-05
Version of Record valid from 2024-09-05
Article History
Received: 21 April 2024
Accepted: 22 August 2024
First Online: 5 September 2024
Declarations
:
: The authors declare no competing interests.